ClinicalTrials.gg
CompletedNCT00828750Updated Sep 17, 2018Results posted

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Phase 3 interventional study of Eltrombopag oral tablets in Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
31st of 36
19 · median 40
Started
2008
the only one that year
Phase 3
9 of 36
none open now
Registered
7th of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 31st largest by enrollment, is the only one that started in 2008, is one of 9 in phase 3, and was the 7th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Purpura, Thrombocytopenic, Idiopathic

Keywords

  • eltrombopag
  • thrombopoietin receptor agonist
  • ITP
  • blood platelet
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has signed and dated written .
  • Subject (>=20 years) diagnosed with ITP.
  • Subject previously enrolled in TRA108109 (NCT00540423) must have completed the treatment and follow-up periods as defined in that protocol.
  • Subject has no intercurrent medical event at risk of thrombosis such as thrombophilia.
  • Prolongation of and activated partial thromboplastin time (aPTT) must be within 1.2 times the with no history of hypercoagulable state.
  • A complete blood count (CBC), within the reference range, with the following exceptions:
  • : patients with haemoglobin level \< the lower limit of normal are eligible for inclusion if hemorrhage is present.
  • >= 1,500/L (1.5x10E9/L) is required for inclusion.
  • The following clinical chemistries MUST NOT exceed 1.2 times the upper limit of the normal reference range: creatinine, total and alkaline phosphatase.
  • The following clinical chemistries MUST NOT exceed 2 times the upper limit of the normal reference range: and AST.
  • Albumin must be not less than 80% of the lower limit of normal.
  • Female subjects must either be:
  • of non- (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or > 1 year), or
  • of childbearing potential and have a negative pregnancy test and agree to use methods specified in the GSK List of Highly Effective Methods for Avoidance of Pregnancy from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Reticulocyte count within the reference range or elevated in case of bleeding.

Exclusion criteria

Exclusion Criteria:

  • Any severe medical condition (cardiac, hepatic or renal disorder) other than chronic ITP. (Note: "Severe" is defined as >= Grade 3 as a rule according to the "Classification of the Severity of Adverse Experiences (PAB/SD Notification No.80, dated 29 June 1992)
  • History of suspected or confirmed arterial or venous thrombosis (e.g., myocardial infarction, deep vein thrombosis) within the last 1 year.
  • History of drug/alcohol abuse or dependence within the last 1 year.
  • Suspected blood disorder other than ITP.
  • Suspected aggregation abnormality.
  • Suspected cyclic thrombocytopenia.
  • Suspected Evans Syndrome.
  • Subjects who met the GSK Liver Stopping Criteria in the previous eltrombopag study TRA108109 (NCT00540423).
  • Current or history of infection or virus or virus infections.
  • Current or history of malignancy that was treated with chemotherapy or radiotherapy.
  • Female subjects who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
  • Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).
  • Treatment with an drug within 30 days preceding the first dose of study medication.
  • Pre-existing cardiovascular disease, or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Treatment

    Eltrombopag oral tablets once daily

    Drug: Eltrombopag oral tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medical product, whether or not related to the product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or its prolongation, results in disability/incapacity, is a congenital anomaly/birth defect, or is another event considered serious. A drug-related AE is any AE that was judged to have a relationship with the study medication by the investigator. The severity of an AE is based on the investigator's clinical judgment.

    Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)

Secondary outcomes

  1. Percentage of Participants Achieving a Platelet Count Greater Than or Equal to 50 Giga Unit (10^9) Per Liter (Gi/L) and Less Than or Equal to 400 Gi/L

    Platelet counts were measured by blood draw.

    Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)

  2. Median Platelet Counts

    Platelet counts were measured by blood draw.

    Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)

  3. Percentage of Participants With a Given Maximum Number of Weeks of Continuous Platelet Count Evaluation Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count Categorized by Weeks on Study Medication (Med.)

    Maximum continuous week (MCW) is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.

    Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)

  4. Median Number of Maximum Continuous Weeks of Maintaining Platelet Counts Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count at Three-Month Intervals

    Maximum continuous week is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.

    Time frame: 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months (13, 26, 39, 52, 65, 78, 91, 104, 117, and 130 weeks)

  5. Percentage of Participants Experiencing Any Bleeding Episode After Dosing With Study Medication

    Any bleeding(s) with an onset on or after the start date of study medication was recorded as a bleeding episode(s).

    Time frame: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)

  6. Percentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication

    Concomitant ITP medications included drugs such as steroids and immunosuppressive drugs. Reduction of concomitant ITP medication was defined as a reduction in dose and/or frequency of administration.

    Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)

  7. Percentage of Participants Initiating Rescue Medication/Treatment During On-Therapy

    Rescue therapy included new ITP medication, an increased dose of a concomitant ITP medication from Baseline (B/L), platelet transfusion, and splenectomy.

    Time frame: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)

07

Results

Posted Dec 1, 2011

Participant flow

Participant flow — Overall Study
MilestoneEltrombopag
Started19
Completed15
Not completed4
Withdrew: Lack of efficacy3
Withdrew: Normal pc remained while no treatment1

Outcome measures

PrimaryNumber of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medical product, whether or not related to the product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or its prolongation, results in disability/incapacity, is a congenital anomaly/birth defect, or is another event considered serious. A drug-related AE is any AE that was judged to have a relationship with the study medication by the investigator. The severity of an AE is based on the investigator's clinical judgment.

Time frame:
From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Reported as:
Number · participants
Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category
participantsEltrombopag
AE19
SAE6
Drug-Related AE5
AE Leading to Withdrawal0
SAE Leading to Withdrawal0
Ongoing AE at the End of Study/Withdrawal15
Mild AE6
Moderate AE13
Severe AE0
SecondaryPercentage of Participants Achieving a Platelet Count Greater Than or Equal to 50 Giga Unit (10^9) Per Liter (Gi/L) and Less Than or Equal to 400 Gi/L

Platelet counts were measured by blood draw.

Time frame:
Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Platelet Count Greater Than or Equal to 50 Giga Unit (10^9) Per Liter (Gi/L) and Less Than or Equal to 400 Gi/L
percentage of participantsEltrombopag
Baseline, n=195.3
Week 1, n=1921.1
Week 2, n=1963.2
Week 3, n=1978.9
Week 4, n=1973.7
Week 8, n=1973.7
Week 12, n=1668.8
Week 16, n=1776.5
Week 20, n=1573.3
Week 24, n=1782.4
Week 28, n=1681.3
Week 32, n=1668.8
Week 36, n=1866.7
Week 40, n=1747.1
Week 44, n=1758.8
Week 48, n=1883.3
Week 52, n=1662.5
Week 56, n=1457.1
Week 60, n=1650.0
Week 64, n=1457.1
Week 68, n=1457.1
Week 72, n=1250.0
Week 76, n=1275.0
Week 80, n=1266.7
Week 84, n=1369.2
Week 88, n=1275.0
Week 92, n=1172.7
Week 96, n=1154.5
Week 100, n=1346.2
Week 104, n=1145.5
Week 108, n=1172.7
Week 112, n=757.1
Week 116, n=785.7
Week 120, n=540.0
Week 124, n=616.7
Week 128, n=425.0
Week 132, n=250.0
Week 136, n=1100
Last Visit/Early Withdrawal Visit, n=1957.9
SecondaryMedian Platelet Counts

Platelet counts were measured by blood draw.

Time frame:
Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Reported as:
Median · Gi/L
Median Platelet Counts
Gi/LEltrombopag
Baseline, n=1920.0 (3 to 117)
Week 1, n=1936.0 (4 to 308)
Week 2, n=1984.0 (14 to 463)
Week 3, n=1985.0 (10 to 194)
Week 4, n=1997.0 (5 to 259)
Week 8, n=19102.0 (5 to 224)
Week 12, n=1685.0 (23 to 238)
Week 16, n=1776.0 (8 to 217)
Week 20, n=1561.0 (7 to 252)
Week 24, n=1770.0 (5 to 255)
Week 28, n=1697.0 (17 to 202)
Week 32, n=1675.0 (9 to 184)
Week 36, n=1873.5 (3 to 233)
Week 40, n=1745.0 (4 to 222)
Week 44, n=1759.0 (3 to 226)
Week 48, n=1871.5 (3 to 224)
Week 52, n=1681.0 (5 to 303)
Week 56, n=1458.0 (19 to 223)
Week 60, n=1648.5 (4 to 252)
Week 64, n=1457.5 (5 to 201)
Week 68, n=1453.5 (3 to 200)
Week 72, n=1251.5 (20 to 188)
Week 76, n=1290.0 (39 to 241)
Week 80, n=1267.5 (7 to 277)
Week 84, n=1386.0 (20 to 280)
Week 88, n=1265.0 (14 to 205)
Week 92, n=1178.0 (22 to 194)
Week 96, n=1157.0 (11 to 236)
Week 100, n=1345.0 (15 to 282)
Week 104, n=1144.0 (8 to 241)
Week 108, n=1169.0 (2 to 318)
Week 112, n=756.0 (15 to 146)
Week 116, n=784.0 (38 to 148)
Week 120, n=521.0 (11 to 294)
Week 124, n=632.0 (8 to 156)
Week 128, n=437.0 (7 to 178)
Week 132, n=234.0 (18 to 50)
Week 136, n=151.0 (51 to 51)
Last Visit/Early Withdrawal Visit, n=1975.0 (7 to 314)
SecondaryPercentage of Participants With a Given Maximum Number of Weeks of Continuous Platelet Count Evaluation Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count Categorized by Weeks on Study Medication (Med.)

Maximum continuous week (MCW) is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.

Time frame:
From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Reported as:
Number · percentage of participants
Percentage of Participants With a Given Maximum Number of Weeks of Continuous Platelet Count Evaluation Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count Categorized by Weeks on Study Medication (Med.)
percentage of participantsEltrombopag
Study Med. =<52 weeks (WKS), MCW=0 week (WK), n=20
Study Med. =<52 WKS, MCW >=1 WK, n=2100
Study Med. =<52 WKS, MCW >=4 WKS, n=2100
Study Med. =<52 WKS, MCW >=7 WKS, n=250.0
Study Med. =<52 WKS, MCW >=10 WKS, n=250.0
Study Med. =<52 WKS, MCW >=13 WKS, n=250.0
Study Med. =<52 WKS, MCW >=16 WKS, n=250.0
Study Med. =<52 WKS, MCW >=19 WKS, n=250.0
Study Med. =<52 WKS, MCW >=22 WKS, n=250.0
Study Med. =<52 WKS, MCW >=25 WKS, n=250.0
Study Med. =<52 WKS, MCW >=28 WKS, n=250.0
Study Med. =<52 WKS, MCW >=31 WKS, n=250.0
Study Med. =<52 WKS, MCW >=34 WKS, n=250.0
Study Med. =<52 WKS, MCW >=37 WKS, n=20
Study Med. =<52 WKS, MCW >=40 WKS, n=20
Study Med. =<52 WKS, MCW >=43 WKS, n=20
Study Med. >52 to =<78 WKS, MCW=0 WK, n=10
Study Med. >52 to =<78 WKS, MCW >=1 WK, n=1100
Study Med. >52 to =<78 WKS, MCW >=4 WKS, n=1100
Study Med. >52 to =<78 WKS, MCW >=7 WKS, n=1100
Study Med. >52 to =<78 WKS, MCW >=10 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=13 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=16 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=19 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=22 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=25 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=28 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=31 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=34 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=37 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=40 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=43 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=52 WKS, n=10
Study Med. >52 to =<78 WKS, MCW >=65 WKS, n=10
Study Med. >78 to =<104 WKS, MCW=0 WK, n=10
Study Med. >78 to =<104 WKS, MCW >=1 WK, n=1100
Study Med. >78 to =<104 WKS, MCW >=4 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=7 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=10 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=13 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=16 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=19 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=22 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=25 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=28 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=31 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=34 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=37 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=40 WKS, n=1100
Study Med. >78 to =<104 WKS, MCW >=43 WKS, n=10
Study Med. >78 to =<104 WKS, MCW >=52 WKS, n=10
Study Med. >78 to =<104 WKS, MCW >=65 WKS, n=10
Study Med. >78 to =<104 WKS, MCW >=78 WKS, n=10
Study Med. >104 to =<130 WKS, MCW=0 WK, n=110
Study Med. >104 to =<130 WKS, MCW >=1 WK, n=11100
Study Med. >104 to =<130 WKS, MCW >=4 WKS, n=1190.9
Study Med. >104 to =<130 WKS, MCW >=7 WKS, n=1190.9
Study Med. >104 to =<130 WKS, MCW >=10 WKS, n=1190.9
Study Med. >104 to =<130 WKS, MCW >=13 WKS, n=1190.9
Study Med. >104 to =<130 WKS, MCW >=16 WKS, n=1181.8
Study Med. >104 to =<130 WKS, MCW >=19 WKS, n=1163.6
Study Med. >104 to =<130 WKS, MCW >=22 WKS, n=1154.5
Study Med. >104 to =<130 WKS, MCW >=25 WKS, n=1145.5
Study Med. >104 to =<130 WKS, MCW >=28 WKS, n=1145.5
Study Med. >104 to =<130 WKS, MCW >=31 WKS, n=1136.4
Study Med. >104 to =<130 WKS, MCW >=34 WKS, n=1136.4
Study Med. >104 to =<130 WKS, MCW >=37 WKS, n=1118.2
Study Med. >104 to =<130 WKS, MCW >=40 WKS, n=1118.2
Study Med. >104 to =<130 WKS, MCW >=43 WKS, n=1118.2
Study Med. >104 to =<130 WKS, MCW >=52 WKS, n=1118.2
Study Med. >104 to =<130 WKS, MCW >=65 WKS, n=119.1
Study Med. >104 to =<130 WKS, MCW >=78 WKS, n=119.1
Study Med. >104 to =<130 WKS, MCW >=91 WKS, n=119.1
Study Med. >104 to =<130 WKS, MCW >=104 WKS, n=110
Study Med. >104 to =<130 WKS, MCW >=117 WKS, n=60
Study Med. >130 WKS, MCW=0 WK, n=40
Study Med. >130 WKS, MCW >=1 WK, n=4100
Study Med. >130 WKS, MCW >=4 WKS, n=450.0
Study Med. >130 WKS, MCW >=7 WKS, n=450.0
Study Med. >130 WKS, MCW >=10 WKS, n=450.0
Study Med. >130 WKS, MCW >=13 WKS, n=425.0
Study Med. >130 WKS, MCW >=16 WKS, n=425.0
Study Med. >130 WKS, MCW >=19 WKS, n=425.0
Study Med. >130 WKS, MCW >=22 WKS, n=425.0
Study Med. >130 WKS, MCW >=25 WKS, n=425.0
Study Med. >130 WKS, MCW >=28 WKS, n=425.0
Study Med. >130 WKS, MCW >=31 WKS, n=425.0
Study Med. >130 WKS, MCW >=34 WKS, n=425.0
Study Med. >130 WKS, MCW >=37 WKS, n=425.0
Study Med. >130 WKS, MCW >=40 WKS, n=425.0
Study Med. >130 WKS, MCW >=43 WKS, n=40
Study Med. >130 WKS, MCW >=52 WKS, n=40
Study Med. >130 WKS, MCW >=65 WKS, n=40
Study Med. >130 WKS, MCW >=78 WKS, n=40
Study Med. >130 WKS, MCW >=91 WKS, n=40
Study Med. >130 WKS, MCW >=104 WKS, n=40
Study Med. >130 WKS, MCW >=117 WKS, n=40
Total, MCW=0 WK, n=190
Total, MCW >=1 WK, n=19100
Total, MCW >=4 WKS, n=1984.2
Total, MCW >=7 WKS, n=1978.9
Total, MCW >=10 WKS, n=1973.7
Total, MCW >=13 WKS, n=1968.4
Total, MCW >=16 WKS, n=1963.2
Total, MCW >=19 WKS, n=1952.6
Total, MCW >=22 WKS, n=1947.4
Total, MCW >=25 WKS, n=1942.1
Total, MCW >=28 WKS, n=1942.1
Total, MCW >=31 WKS, n=1936.8
Total, MCW >=34 WKS, n=1936.8
Total, MCW >=37 WKS, n=1921.1
Total, MCW >=40 WKS, n=1921.1
Total, MCW >=43 WKS, n=1910.5
Total, MCW >=52 WKS, n=1711.8
Total, MCW >=65 WKS, n=175.9
Total, MCW >=78 WKS, n=166.3
Total, MCW >=91 WKS, n=156.7
Total, MCW >=104 WKS, n=150
Total, MCW >=117 WKS, n=100
SecondaryMedian Number of Maximum Continuous Weeks of Maintaining Platelet Counts Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count at Three-Month Intervals

Maximum continuous week is measured as the longest period (weeks) for which a participant continuously maintained platelet counts greater than or equal to 50 Gi/L and greater than or equal to twice the Baseline count.

Time frame:
3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months (13, 26, 39, 52, 65, 78, 91, 104, 117, and 130 weeks)
Reported as:
Median · weeks
Median Number of Maximum Continuous Weeks of Maintaining Platelet Counts Greater Than or Equal to 50 Gi/L and Greater Than or Equal to Twice the Baseline Count at Three-Month Intervals
weeksEltrombopag
Total, n=1919.0 (1 to 91)
3 Months (13 Weeks), n=185.0 (0 to 11)
6 Months (26 Weeks), n=1910.0 (0 to 24)
9 Months (39 Weeks), n=1912.0 (0 to 36)
12 Months (52 Weeks), n=1714.0 (0 to 36)
15 Months (65 Weeks), n=1714.0 (0 to 40)
18 Months (78 Weeks), n=1615.0 (0 to 53)
21 Months (91 Weeks), n=1514.0 (0 to 64)
24 Months (104 Weeks), n=1519.0 (0 to 76)
27 Months (117 Weeks), n=1017.5 (0 to 91)
30 Months (130 Weeks), n=47.5 (3 to 40)
SecondaryPercentage of Participants Experiencing Any Bleeding Episode After Dosing With Study Medication

Any bleeding(s) with an onset on or after the start date of study medication was recorded as a bleeding episode(s).

Time frame:
Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Bleeding Episode After Dosing With Study Medication
percentage of participantsEltrombopag
Baseline, n=1963
Week 1, n=1932
Week 2, n=1921
Week 3, n=1916
Week 4, n=195
Week 8, n=1911
Week 12, n=1613
Week 16, n=1712
Week 20, n=1540
Week 24, n=176
Week 28, n=1625
Week 32, n=1619
Week 36, n=1839
Week 40, n=1735
Week 44, n=1724
Week 48, n=1822
Week 52, n=1631
Week 56, n=1429
Week 60, n=1613
Week 64, n=1421
Week 68, n=1429
Week 72, n=128
Week 76, n=128
Week 80, n=1225
Week 84, n=130
Week 88, n=128
Week 92, n=119
Week 96, n=119
Week 100, n=138
Week 104, n=1127
Week 108, n=1127
Week 112, n=714
Week 116, n=70
Week 120, n=50
Week 124, n=633
Week 128, n=425
Week 132, n=250
Week 136, n=10
Last Visit/Early Withdrawal, n=1921
SecondaryPercentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication

Concomitant ITP medications included drugs such as steroids and immunosuppressive drugs. Reduction of concomitant ITP medication was defined as a reduction in dose and/or frequency of administration.

Time frame:
From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Reported as:
Number · percentage of participants
Percentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication
percentage of participantsEltrombopag
Percentage of Participants With a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication87
SecondaryPercentage of Participants Initiating Rescue Medication/Treatment During On-Therapy

Rescue therapy included new ITP medication, an increased dose of a concomitant ITP medication from Baseline (B/L), platelet transfusion, and splenectomy.

Time frame:
From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Reported as:
Number · percentage of participants
Percentage of Participants Initiating Rescue Medication/Treatment During On-Therapy
percentage of participantsEltrombopag
Any Rescue Therapy21
New ITP Medication11
Increase in Concomitant ITP Medication from B/L11
Platelet Transfusion0
Splenectomy0

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) with an onset on or after the start date of study medication were collected until the end of the study (up to 981 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag—6/19 (31.6%)19/19 (100%)
Most frequent serious events
Most frequent serious events
EventEltrombopag
CataractEye disorders2/19
Abdominal painGastrointestinal disorders1/19
Mallory-Weiss syndromeGastrointestinal disorders1/19
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/19
OsteonecrosisMusculoskeletal and connective tissue disorders1/19
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/19
Cystitis-like symptomRenal and urinary disorders1/19
MenorrhagiaReproductive system and breast disorders1/19
Most frequent other events
Showing 10 of 76
Most frequent other events
EventEltrombopag
NasopharyngitisInfections and infestations12/19
HeadacheNervous system disorders4/19
BronchitisInfections and infestations3/19
DiarrhoeaGastrointestinal disorders3/19
Iron deficiency anaemiaBlood and lymphatic system disorders3/19
MyalgiaMusculoskeletal and connective tissue disorders3/19
EczemaSkin and subcutaneous tissue disorders3/19
InsomniaPsychiatric disorders3/19
HypertensionVascular disorders3/19
CystitisInfections and infestations2/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag
Mean54.7 ± 13.57
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female12
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Eltrombopag
Asian - Japanese Heritage19
08

Study locations

6 sites
  • GSK Investigational Site
    Gifu, 503-8502, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Ibaraki, 305-8576, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Osaka, 596-8501, Japan
  • GSK Investigational Site
    Tokyo, 160-8582, Japan
09

References and documents

Publications

  • Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013 Sep;98(3):323-30. doi: 10.1007/s12185-013-1401-1. Epub 2013 Jul 30. PubMed 23896965 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2009
First posted
Jan 26, 2009
Start
May 2008
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Dec 1, 2011
Last update
Sep 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00828750
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 26, 2009
Start date
May 2008
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Dec 1, 2011
Last update
Sep 17, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion